Healthcare Industry News: Allergan
News Release - March 24, 2006
Allergan Receives Positive Opinion for GANFORT(R) (LUMIGAN(R)/Timolol Combination) in European UnionIRVINE, Calif.--(HSMN NewsFeed)--March 24, 2006--Allergan, Inc. (NYSE:AGN ) today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve GANFORT®, Allergan's LUMIGAN®/timolol combination product (bimatoprost/timolol ophthalmic solution) for the treatment of glaucoma. The CHMP opinion serves as the basis for a European Commission approval, which is expected to be finalized in the second quarter of 2006.
GANFORT® is indicated for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
"Adherence to therapy is an integral factor in the successful treatment of glaucoma and ocular hypertension. Combination therapies often reduce the number of medications required and can aid patients with compliance," said Dr. Scott Whitcup, Allergan's Executive Vice President, Research & Development. "We are very pleased to have received this positive opinion for GANFORT® in the European Union and to present physicians and their patients with this latest advance in combination therapy for the treatment of glaucoma, a leading cause of preventable blindness worldwide."
About Allergan, Inc.
Allergan, Inc., with headquarters in Irvine, California, is a technology-driven, global specialty pharmaceutical and medical device company that develops and commercializes innovative products for the ophthalmology, neurosciences, medical dermatology, medical aesthetics and other specialty markets. Allergan is dedicated to delivering value to its customers, satisfying unmet medical needs, and improving people's lives.
This press release contains "forward-looking statements," including, among other statements, the statements by Dr. Whitcup, statements regarding research and development outcomes, efficacy, and market and product potential. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Allergan's expectations and projections. Risks and uncertainties include general industry and pharmaceutical market conditions; general domestic and international economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents obtained by competitors; challenges inherent in product marketing such as the unpredictability of market acceptance for new pharmaceutical and biologic products and/or the acceptance of new indications for such products; domestic and foreign health care reforms; the timing and uncertainty of the research and development and regulatory processes; trends toward managed care and health care cost containment; and governmental laws and regulations affecting domestic and foreign operations. Allergan expressly disclaims any intent or obligation to update these forward-looking statements except as required to do so by law.
Additional information concerning these and other risk factors can be found in press releases issued by Allergan, as well as Allergan's public periodic filings with the Securities and Exchange Commission, including the discussion under Item 1A of Part I, "Risk Factors," in Allergan's 2005 Form 10-K. Copies of Allergan's press releases and additional information about Allergan is available on the World Wide Web at www.Allergan.com or you can contact the Allergan Investor Relations Department by calling 1-714-246-4636.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAllergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity